The utilization of drug-polymer interactions for improving the chemical stability of hot-melt extruded solid dispersions

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 2, 2014, Pages 285-296

  Guo, Zhefei ^a   Lu, Ming ^a   Li, Yongcheng ^a   Pang, Huishi ^a   Lin, Ling ^a   Liu, Xu ^a   Wu, Chuanbin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

amorphous solid dispersion; chemical stability; hot melt extrusion; hydrogen bond; interaction

Indexed keywords

DIFLUNISAL; HYDROXYPROPYLMETHYLCELLULOSE; POLYMER; POVIDONE;

ARTICLE; CHEMICAL INTERACTION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG DEGRADATION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOT MELT EXTRUSION; HYDROGEN BOND; INFRARED SPECTROSCOPY; MELTING POINT; SCANNING ELECTRON MICROSCOPY; TEMPERATURE SENSITIVITY; THERMOSTABILITY; X RAY DIFFRACTION;

AMORPHOUS SOLID DISPERSION; CHEMICAL STABILITY; HOT-MELT EXTRUSION; HYDROGEN BOND; INTERACTION;

CHEMISTRY, PHARMACEUTICAL; DIFLUNISAL; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; FREEZING; HOT TEMPERATURE; HUMANS; POLYMERS; SOLUBILITY; SOLUTIONS;

EID: 84892732718     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12145     Document Type: Article

References (29)

1. Hancock BC, Zografi G,. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 1997; 86: 1-12.
2. Puri V, et al. Barrier coated drug layered particles for enhanced performance of amorphous solid dispersion dosage form. J Pharm Sci 2012; 101: 342-353.
3. Janssens S, Van den Mooter G,. Review: physical chemistry of solid dispersions. J Pharm Pharmacol 2009; 61: 1571-1586.
4. Qian F, et al. Drug-polymer solubility and miscibility: stability consideration and practical challenges in amorphous solid dispersion development. J Pharm Sci 2010; 99: 2941-2947.
5. Yu L,. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev 2001; 48: 27-42.
6. Albers J, et al. Mechanism of drug release from polymethacrylate-based extrudates and milled strands prepared by hot-melt extrusion. Eur J Pharm Biopharm 2009; 71: 387-394.
7. Suwardie H, et al. Rheological study of the mixture of acetaminophen and polyethylene oxide for hot-melt extrusion application. Eur J Pharm Biopharm 2011; 78: 506-512.
8. Frank KJ, et al. Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: true supersaturation vs. apparent solubility enhancement. Int J Pharm 2012; 437: 288-293.
9. Ghosh I, et al. Key considerations for optimization of formulation and melt-extrusion process parameters for developing thermosensitive compound. Pharm Dev Technol 2012; 17: 502-510.
10. DiNunzio JC, et al. Fusion production of solid dispersions containing a heat-sensitive active ingredient by hot melt extrusion and Kinetisol® dispersing. Eur J Pharm Biopharm 2010; 74: 340-351.
11. Liu X, et al. Improving the chemical stability of amorphous solid dispersion with cocrystal technique by hot melt extrusion. Pharm Res 2012; 29: 806-817.
12. Childs SL, et al. Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine. CrystEngComm 2008; 10: 856-864.
13. Lakshman JP, et al. Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug. Mol Pharm 2008; 5: 994-1002.
14. Ghosh I, et al. Comparison of HPMC based polymers performance as carriers for manufacture of solid dispersions using the melt extruder. Int J Pharm 2011; 419: 12-19.
15. 2 as a temporary plasticizer. Int J Pharm 2006; 327: 45-50.
16. Abu-Diak OA, et al. Understanding the performance of melt-extruded poly(ethylene oxide)-bicalutamide solid dispersions: characterisation of microstructural properties using thermal, spectroscopic and drug release methods. J Pharm Sci 2012; 101: 200-213.
17. Qi S, et al. Characterisation of solid dispersions of paracetamol and EUDRAGIT® E prepared by hot-melt extrusion using thermal, microthermal and spectroscopic analysis. Int J Pharm 2008; 354: 158-167.
18. 17O solid-state NMR as a sensitive probe of hydrogen bonding in crystalline and amorphous solid forms of diflunisal. Mol Pharm 2013; 10: 3433-3446.
19. Marsac P, et al. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm Res 2006; 23: 2417-2426.
20. Wassel AA,. Thermal stability of some anti-inflammatory pharmaceutical drugs and determination of purity. J Phys Chem A 2010; 1: 1-8.
21. DiNunzio JC, et al. Melt extrusion. In:, Williams RO, III, ed. Formulating Poorly Water Soluble Drugs. New York, NY: Springer, 2012: 311-362.
22. Martínez-Ohárriz MC, et al. Solid dispersions of diflunisal-PVP: polymorphic and amorphous states of the drug. Drug Dev Ind Pharm 2002; 28: 717-725.
23. Marsac P, et al. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharm Res 2009; 26: 139-151.
24. Taylor L, Zografi G,. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res 1997; 14: 1691-1698.
25. Djuric D, et al. Characterization of polymeric micelles from solid solutions with a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer and itraconazole. 38th Annual Meeting & Exposition of the Gontrolled Release Society, Maryland, 2011. Available at: http://www.pharma- ingredients.basf.com/Documents/ENP/Poster/EN/GENPMD343.pdf.
26. Rumondor ACF, et al. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture. Mol Pharm 2009; 6: 1492-1505.
27. Lin DX, Huang YB,. A thermal analysis method to predict the complete phase diagram of drug-polymer solid dispersions. Int J Pharm 2010; 399: 109-115.
28. Sun Y, et al. Solubilities of crystalline drugs in polymers: an improved analytical method and comparison of solubilities of indomethacin and nifedipine in PVP, PVP/VA, and PVAc. J Pharm Sci 2010; 99: 4023-4031.
29. Tao J, et al. solubility of small-molecule crystals in polymers: d-mannitol in PVP, indomethacin in PVP/VA, and nifedipine in PVP/VA. Pharm Res 2009; 26: 855-864.